CDSCO panel nod to Novartis Ruxolitinib for acute and chronic graft versus host disease - Video
|
Overview
In response to the pharma major Novartis proposal for additional indication of Ruxolitinib Tablets 5/10/15/20 mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has granted permission for additional indication of Ruxolitinib for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies.
This nod is subjected to condition that the firm should submit safety and efficacy data of ongoing Global study and Post Marketing data related to said indication within one year from the approval for evaluation by the committee for its continued marketing.
For more details, check out the full story on the link below:
Novartis Ruxolitinib Gets CDSCO Panel Okay For Acute And Chronic Graft Versus Host Disease
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751